The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Anthrax Vaccine Market Expected To Change From 2026 To 2030?
The anthrax vaccine market size has consistently expanded in recent years. This market is set to increase from $11.77 billion in 2025 to $12.33 billion in 2026, at a compound annual growth rate (CAGR) of 4.7%. The expansion observed in the historical period was driven by the significant prevalence of anthrax in livestock, government-led vaccination campaigns, advances in immunology research, restricted vaccine production capacity, and greater awareness of occupational exposure.
The anthrax vaccine market is projected to experience consistent expansion over the coming years, anticipated to reach $14.49 billion by 2030, driven by a compound annual growth rate (CAGR) of 4.1%. This growth during the projected period can be ascribed to several factors, including the creation of recombinant and advanced vaccines, an increasing need for both human and animal preventive measures, improvements in vaccine administration methods, the enlargement of biodefense initiatives, and partnerships formed between pharmaceutical and defense industries. Key developments expected during this timeframe encompass sophisticated vaccine compositions, broadened immunization campaigns, breakthroughs in cold chain and storage solutions, enhanced biodefense and pandemic readiness, and vaccination efforts led by government and military bodies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp
What Key Factors Are Shaping The Anthrax Vaccine Market Landscape?
The expanding incidence of infectious diseases is anticipated to drive the anthrax vaccine market forward. Infectious diseases, defined as ailments stemming from pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, can transmit directly or indirectly, often leading to symptoms ranging from mild to severe, and potentially fatal. The heightened prevalence of these diseases is influenced by global demographic shifts, urbanization, changes in environment and land use, and evolving human behaviors. The anthrax vaccine primarily offers protection against anthrax, with ongoing research exploring its broader utility in preventing other infectious diseases through its immunogenic properties and adaptability. For example, the Council on Foreign Relations, in February 2023, stated that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of established infectious diseases had zoonotic origins. Furthermore, zoonoses globally account for 2.7 million human fatalities and 2.5 billion disease episodes annually. Consequently, the escalating occurrence of diseases is a key factor propelling the growth of the anthrax vaccine market.
How Are Segments Identified Within The Anthrax Vaccine Market Segment Framework?
The anthrax vaccine market covered in this report is segmented –
1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine
2) By Application Type: Animal Use, Human Use
3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels
Subsegments:
1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine
2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine
What Trends Are Affecting The Direction Of The Anthrax Vaccine Market?
Major companies within the anthrax vaccine market are prioritizing the creation of innovative products and obtaining FDA approvals for their vaccines, aiming to guarantee their safety, efficacy, and availability for individuals at risk of anthrax exposure. FDA approval confirms that a vaccine has undergone thorough testing in clinical trials and is proven safe for public consumption, thereby protecting people from potential adverse reactions. For example, in July 2023, Emergent BioSolutions Inc., a biopharmaceutical company headquartered in the U.S., received approval from the U.S. Food and Drug Administration (FDA) for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly identified as AV7909. This approval was founded on data from a Phase 2 trial evaluating Cyfendus’s non-interference with antibacterial drugs and Phase 3 clinical research comparing its immunogenicity and safety to BioThrax, the earlier anthrax vaccine. Additionally, advancing safer and more potent adjuvants is essential to address reactogenicity-related challenges and enhance the overall efficiency of anthrax vaccines.
Who Are The Companies Competing Within The Anthrax Vaccine Market?
Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.
Get The Full Anthrax Vaccine Market Report:
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Which Region Dominates The Anthrax Vaccine Market By Market Share?
North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Anthrax Vaccine Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Browse Through More Reports Similar to the Global Anthrax Vaccine Market 2026, By The Business Research Company
Anthrax Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Anthrax Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report
Anthracycline Market Report 2026
https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model